Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

Table 2 Subgroup analysis

	MACE			Cardiovascular death			Major bleeding			Net clinical events
	RR(95% CI)	I² (%)	p	RR(95% CI)	I² (%)	p	RR(95% CI)	I² (%)	p	RR(95% CI)	I² (%)	p
Strategies to overcome HPR			0.02			0.26			0.60			<0.001
Repeated LD	0.06(0.01–0.29)	0	<0.001	0.15(0.02–1.18)	0	0.07	1.02(0.21–5.02)	0	0.98	0.14(0.05–0.38)	0	<0.001
Increased MD	0.56(0.39–0.96)	66	0.003	0.41(0.20–0.84)	0	0.01	0.69(0.38–1.25)	0	0.22	0.59(0.44–0.81)	10	0.001
Switch to prasugrel	0.77(0.28–2.15)	49	0.62				1.01(0.49–2.11)	5	0.97	1.00(0.81–1.24)	0	1.00
Intervention duration			<0.001			0.06			0.26			<0.001
≤1 month	0.16(0.07–0.37)	0	<0.001	0.17(0.04–0.75)	0	0.02	1.51(0.43–5.34)	0	0.52	0.21(0.11–0.42)	0	<0.001
>1 month	0.81(0.58–1.14)	65	0.23	0.75(0.45–1.25)	6	0.27	0.71(0.51–0.99)	0	0.05	0.93(0.75–1.14)	54	0.47
Follow up duration			0.03			0.11			0.91			<0.001
1 month	0.09(0.02–0.40)	0	0.001	0.15(0.02–1.18)	0	0.07	1.02(0.21–5.02)	0	0.98	0.15(0.06–0.38)	0	<0.001
6 months	0.48(0.21–1.11)	38	0.09	0.30(0.09–1.00)	0	0.05	0.77(0.44–1.36)	11	0.38	0.72(0.49–1.08)	2	0.11
12 months	0.73(0.46–1.14)	75	0.16	0.84(0.49–1.15)	0	0.53	0.72(0.49–1.08)	0	0.11	0.93(0.72–1.21)	71	0.60
Platelet function device			0.05			0.27			0.72			<0.001
VerifyNow	0.94(0.70–1.27)	37	0.69	0.69(0.37–1.32)	39	0.26	0.76(0.54–1.05)	0	0.10	0.98(0.82–1.16)	26	0.79
VASP	0.20(0.05–0.91)	58	0.04	0.38(0.16–0.89)	0	0.03	1.02(0.21–5.02)	0	0.98	0.27(0.12–0.59)	38	0.001

ISSN: 1471-2261